Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NPM1 | P06748 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31530744 | 1.00 | TDP1 (0.50) | TDP1PABPC1PIK3R1PIK3CAHTT | |
| SCHEMBL12503088 | 0.86 | RXFP1 (0.49) | TDP1PABPC1PIK3R1PIK3CAHTT | |
| SCHEMBL12502796 | 0.86 | RXFP1 (0.49) | TDP1PABPC1PIK3R1PIK3CAHTT | |
| SCHEMBL30179258 | 0.85 | PABPC1 (0.58) | PABPC1PIK3R1PIK3CAHTTBACE1 | |
| SCHEMBL28634341 | 0.85 | PABPC1 (0.58) | PABPC1PIK3R1PIK3CAHTTBACE1 | |
| SCHEMBL483060 | 0.85 | PABPC1 (0.58) | PABPC1PIK3R1PIK3CAHTTBACE1 | |
| SCHEMBL932710 | 0.82 | KDM4E (0.52) | PABPC1PIK3R1PIK3CAHTTNT5E | |
| SCHEMBL23234459 | 0.81 | HTT (0.43) | PABPC1PIK3R1PIK3CAHTTBACE1 | |
| SCHEMBL15196675 | 0.80 | PABPC1 (0.54) | PABPC1PIK3R1PIK3CAHTTBACE1 | |
| SCHEMBL28198392 | 0.80 | PABPC1 (0.54) | PABPC1PIK3R1PIK3CAHTTBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4592289-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-07-30 | — | — | EP | disclosed |
| EP-4567038-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025077857-A1 | USE OF PRMT5 INHIBITOR IN TREATMENT OF TUMORS OR CANCERS | 上海湃隆生物科技有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-12-24 | — | — | US | disclosed |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-09-05 | — | — | US | disclosed |
| WO-2024067433-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024032572-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-20210198259-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-07-01 | — | — | US | disclosed |
| EP-3807282-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-21 | — | — | EP | disclosed |
| CN-112204032-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-4200748-A | ANXIOLYTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CDK1, CSNK1A1, CSNK1G1 | TDP1 292/4885PABPC1 2711/4885PIK3R1 397/4885 |
| US-12173002-B2 | PRMT5 inhibitors and methods of use | PRMT5, PRMT1, PRMT7 | TDP1 498/4885PABPC1 1299/4885PIK3R1 4110/4885 |
| US-20210198259-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | HRH4, HRH2, HRH1 | TDP1 4024/4885PABPC1 4041/4885PIK3R1 2708/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TDP1 4213/4885PABPC1 4782/4885PIK3R1 1997/4885 |
| US-20250051331-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT7 | TDP1 899/4885PABPC1 1494/4885PIK3R1 2220/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TDP1 4213/4885PABPC1 4782/4885PIK3R1 1997/4885 |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT1, PRMT5, PRMT6 | TDP1 808/4885PABPC1 2321/4885PIK3R1 2916/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | TDP1 4213/4885PABPC1 4782/4885PIK3R1 1997/4885 |
| US-20240294528-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT5, PRMT1, PRMT3 | TDP1 404/4885PABPC1 1097/4885PIK3R1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.